PHNOM PENH, Cambodia, Jan. 6, 2026 /PRNewswire/ — The Perceiving China & Cambodia Cultural Activities were held in Cambodia from December 13 to 16, 2025, injecting new vitality into China–Cambodia friendship and people-to-people exchanges.

Organized by China Intercontinental Press & Media Co., Ltd., the activities featured a cultural bazaar, a China–Cambodia relation symposium, and the launch of the “China–Cambodia Youth Speak” Vlog Competition. The events were supported by multiple Cambodian institutions, including the Ministry of Culture and Fine Arts of Cambodia, the National Television of Cambodia, the Royal Academy of Cambodia, and the APSARA National Authority.

The cultural bazaar, featuring nearly 40 booths, attracted large crowds with displays of intangible cultural heritage, cultural and creative products, technological innovations, and specialty foods. Chinese elements such as Hanfu, calligraphy, robots, and intelligent dolls were presented alongside Cambodian traditional crafts, including leather carving, palm-leaf weaving, sampot, and traditional masks, drawing enthusiastic participation and interaction from visitors.

Lasting for two days, the cultural bazaar adopted a people-centered, down-to-earth, and warm approach, attracting a large number of local residents and tourists from various countries to participate voluntarily. It served as a vivid platform for promoting mutual learning among civilizations and enhancing people-to-people friendship.

Va Bophary, an official from Cambodia’s Ministry of Culture and Fine Arts, said the event not only showcased the distinctive cultures and civilizations of Cambodia and China, but also reflected the long-standing friendship between the two peoples, helping to deepen cultural and emotional ties between the two countries.

Vinh Bun Eang, an official from Cambodia’s Ministry of Education, Youth and Sport, noted that the joint presentation of Cambodian traditional costumes, exquisite leather carvings and specialty foods alongside Chinese Hanfu, calligraphy and cuisine created a harmonious and vibrant atmosphere for people-to-people exchanges.

During the activities, a China–Cambodia relation symposium was held at the Royal Academy of Cambodia. Co-hosted by the Royal Academy of Cambodia, China Intercontinental Press & Media Co., Ltd., and Jiujiang University, and organized by the Confucius Institute at the Royal Academy of Cambodia, the event focused on the themes of “Deepening Understanding for Balanced Development” and “Cultural Connectivity for Mutual Learning among Civilizations.”

Experts and scholars engaged in in-depth discussions on topics including China–Cambodia strategic cooperation, balanced international relations, people-to-people connectivity, Chinese language education, and tourism cooperation, while also sharing insights within the framework of Belt and Road cooperation.

Dr. Tang Qifang, an associate researcher at the China Institute of International Studies, said that as China–Cambodia relations have been elevated to an all-weather China–Cambodia community with a shared future in the new era, the two sides should further deepen political mutual trust at a higher level, expand higher-quality mutually beneficial cooperation, consolidate higher-level security safeguards, conduct people-to-people exchanges more frequently, and strengthen strategic coordination to higher standards.

Dr. Ka Mathul, Deputy Director International Relations Institute of Cambodia, Royal Academy of Cambodia, shared views on how Cambodia can balance international relations and maintain sound development amid the current geopolitical environment. H.E. Dr. Hong Kim Cheang, Under Secretary of State at the Ministry of Education, Youth and Sport of Cambodia, introduced the current situation and future prospects of Chinese language education within Cambodia’s national education system. The symposium provided an important platform for the two countries to deepen strategic coordination and promote people-to-people and cultural exchanges, demonstrating their firm commitment to building a China–Cambodia community with a shared future.

The “China–Cambodia Youth Talk” Vlog Competition was officially launched during the event, with Chinese and international young participants organized to conduct field visits and creative filming at Angkor Wat. The competition aims to encourage youth from both countries to tell stories of China–Cambodia friendship through visual storytelling and showcase achievements in people’s livelihood cooperation. Outstanding entries collected in the follow-up will be showcased on major domestic and international mainstream media as well as new media platforms. Guan Hong, deputy general manager of China Intercontinental Press & Media Co., Ltd., the organizer of the event, said that youth are the hope and backbone of China–Cambodia friendship, expressing the expectation that more touching stories of “China and Cambodia as one family” will be told from a youthful perspective.

Through sustained and diverse activities and multi-dimensional communication, the Perceiving China & Cambodia Cultural Activities will continue to expand the breadth and depth of China–Cambodia people-to-people exchanges and cooperation, consolidate the social foundation of bilateral friendship, promote mutual learning among civilizations, and inject lasting momentum into the long-term and stable development of China–Cambodia relations.

BANGKOK and ANTWERP, Belgium, Jan. 6, 2026 /PRNewswire/ — Thailand is set to become the stage for a brand-new chapter in the story of Tomorrowland, as preparations officially bring one of the world’s most iconic music festivals to Asia for the very first time this December 11–13, 2026.

© Tomorrowland

The festival organization has confirmed its partnership with the Thai Government, Tourism Authority of Thailand (TAT), and the operational structure for Tomorrowland Thailand. Chosen over several other Asian destinations, Thailand’s appointment underscores its growing influence on the global stage of music, innovation, and experience-driven tourism. A festival of this magnitude is expected to generate a significant impact on the local and national economy, boosting tourism, hospitality, and creative industries while welcoming festivalgoers from across the globe.

“Hosting Tomorrowland in Thailand marks an important milestone in our ambition to position the country as a leader in global tourism and creative experiences. We look forward to welcoming people from all over the world to discover the beauty, culture, and hospitality of Thailand.”
— Governor Tourism Authority of Thailand

Tomorrowland has confirmed Wisdom Valley in Pattaya (Khao Mai Kaew, Bang Lamung District, Chonburi Province) as the home of the festival. The 237-acre site (600 rai) will feature several spectacular stages, The iconic CORE and Freedom stages will also appear in Asia for the first time, alongside new stages and experiences created exclusively for Thailand. The festival aims to welcome over 50,000 people per day across three days.

“Expanding Tomorrowland to a new continent is a milestone we approach with great respect and excitement. Thailand feels like the right place, not only because of its beauty and energy, but also because of the shared ambition to create something meaningful and world-class together. This is the beginning of a long-term story.”
— Bruno Vanwelsenaers, CEO WEAREONE.world. 

As preparations accelerate, Tomorrowland’s Belgian organization is working closely with a dedicated local team to bring the festival’s world-renowned expertise in electronic music, stage design, storytelling, and large-scale production to Thailand. The collaboration will ensure that the full signature Tomorrowland experience, known for its groundbreaking stages, imaginative worlds, and exceptional attention to detail, is fully brought to life in Asia. With two festivals in Europe, one in South America, and now the first full-scale Asian edition taking shape, a new piece of the Tomorrowland story is being written. 

APIA, Samoa, Jan. 6, 2026 /PRNewswire/ — Phemex, a user-first crypto exchange, has unveiled a strategic dual-track program designed to bolster the trading ecosystem amidst a resurgent crypto landscape in early 2026. By simultaneously launching Apex Competition Season 3 and the New Year Futures Boost, the exchange reinforces its commitment to fostering a meritocratic and resilient trading environment for both professional and emerging traders.

As Phemex’s signature recurring league, Apex Season 3 breaks the traditional “winner-takes-all” mold often dominated by high-capital whales. Through a sophisticated multi-track ranking system — spanning Daily, Weekly, and Monthly leaderboards — the competition levels the playing field. This inclusive structure with a  $450,000 prize pool ensures that success is defined by trading acumen rather than capital depth, allowing truly insightful traders to claim the prestige and rewards they deserve, regardless of their portfolio size.

Complementing the competitive arena, the New Year Futures Boost acts as an incubator for emerging talent. Backed by a $200,000 risk-mitigation fund, this initiative lowers the psychological barriers to entry through profit optimization and loss protection mechanisms. It empowers newer traders to gain real-market experience and build confidence, preparing them for future competitive participation.

The New Year Futures Boost runs until Jan 19, while the Apex Competition continues through Feb 1, 2026. Together, they reflect Phemex’s broader product and platform philosophy: to design trading environments that adapt to different user needs, experience levels, and risk profiles. Phemex aims to create a more accessible, sustainable, and user-centered trading ecosystem, consistent with its positioning as a platform built for users first.

About Phemex
Founded in 2019, Phemex is a user-first crypto exchange trusted by over 10 million traders worldwide. The platform offers spot and derivatives trading, copy trading, and wealth management products designed to prioritize user experience, transparency, and innovation. With a forward-thinking approach and a commitment to user empowerment, Phemex delivers reliable tools, inclusive access, and evolving opportunities for traders at every level to grow and succeed.

For more information, please visit: https://phemex.com/ 

Anticipated advancements in weight loss, diabetes, oncology, rare conditions and protein degraders poised to reshape patient care

LONDON, Jan. 6, 2026 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today released its 2026 Drugs to Watch report, identifying eleven therapies expected to deliver significant clinical impact and strong commercial potential over the coming year. The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve blockbuster status or transform care within five years. Drugs to Watch has consistently identified therapies that redefine patient care, with over 110 featured to date, making it a central reference for tracking innovation in the pharmaceutical sector.

Drawing on Clarivate integrated data assets and AI-powered intelligence, the report identifies emerging therapies that may achieve blockbuster status or drive meaningful transformation in patient care. The analysis reflects the interplay of scientific progress, regulatory change and evolving competitive dynamics as companies navigate increasingly complex global markets.

Henry Levy, President, Life Sciences & Healthcare, Clarivate, said: “The pharmaceutical landscape in 2026 will be defined by both unprecedented innovation and increasing complexity. From metabolic disease to rare conditions and precision therapies, the ability to anticipate emerging drug trends and understand shifting patient and market dynamics will be critical. This year’s Drugs to Watch report highlights not only therapies with the potential to transform care but also the broader trends shaping the industry. By leveraging anticipatory intelligence and advanced analytics, companies can make more informed decisions, prioritize meaningful innovation and ultimately bring transformative treatments to patients faster.”

This year’s Drugs to Watch illustrate the intersection of breakthrough science and patient-focused solutions in a rapidly evolving healthcare environment. Key therapies featured in the Drugs to Watch 2026 report, include:

Orforglipron developed by Eli Lilly and Co | Obesity and T2DM
A once-daily, oral small-molecule GLP-1 RA for managing overweight/obesity and T2DM, also under investigation for obstructive sleep apnea and hypertension in individuals with obesity.

Retatrutide developed by Eli Lilly and Co | Obesity and T2DM
A once-weekly subcutaneous triple GLP-1, GIP and glucagon RA for managing overweight, obesity and T2DM, also under evaluation for osteoarthritis, low back pain, cardiovascular and kidney complications, NAFLD/MASH and obesity-related sleep apnea.

Exdensur (depemokimab) developed by GSK | Asthma
A monoclonal antibody targeting IL-5, administered subcutaneously twice yearly to treat asthma in adolescents and adults, also under investigation for CRSwNP, EGPA and hypereosinophilic syndrome.

Icotrokinra developed by Johnson & Johnson | Plaque psoriasis
An IL-23 receptor antagonist, administered once daily orally to treat plaque psoriasis, also under evaluation for psoriatic arthritis and ulcerative colitis.

VOYXACT® (sibeprenlimab) developed by Otsuka Pharmaceutical Co Ltd | Immunoglobulin A nephropathy (IgAN)
A monoclonal antibody targeting APRIL, administered subcutaneously every four weeks to treat IgAN, also under evaluation for Sjögren’s syndrome.

Tolebrutinib developed by Sanofi | Multiple sclerosis
A Bruton tyrosine kinase (BTK) inhibitor, administered once daily orally to treat non-relapsing secondary progressive multiple sclerosis.

Gedatolisib developed by Celcuity | Breast cancer
A pan-PI3K/mTOR inhibitor, administered intravenously once weekly for three weeks in a 28-day cycle to treat HR-positive/HER2-negative metastatic breast cancer, also under evaluation for metastatic castration-resistant prostate cancer.

INLEXZO™ (TAR-200) developed by Johnson & Johnson | Bladder cancer
An antimetabolite nucleoside analog administered intravesically via the TAR-200 drug delivery system every three weeks (induction) and then every 12 weeks (maintenance) to treat BCG-unresponsive high-risk non-muscle invasive bladder cancer, also under evaluation for muscle-invasive bladder cancer.

Relacorilant developed by Corcept Therapeutics Inc | Ovarian cancer and hypercortisolism (Cushing syndrome)
A selective glucocorticoid receptor antagonist (SGRA), administered orally daily to treat platinum-resistant ovarian cancer, Cushing syndrome and hypercortisolism linked to adrenal adenoma or hyperplasia, is also under evaluation for prostate cancer.

BGB-16673 developed by BeOne Medicines | Chronic lymphocytic leukemia/small lymphocytic lymphoma
A BTK-targeting chimeric degradation activation compound (CDAC), administered once daily orally to treat relapsed or refractory CLL and SLL, also under investigation for Waldenstrom’s macroglobulinemia, other B-cell malignancies, including MCL and FL and chronic spontaneous urticaria.

Mezigdomide by Bristol Myers Squibb | Multiple myeloma
Mezigdomide, a second-generation CELMoD therapy administered orally to treat relapsed or refractory multiple myeloma, is designed to degrade Ikaros and Aiolos, key transcription factors in hematopoietic cell development, producing both anti-myeloma and immune-stimulatory effects.

The Drugs to Watch 2026 report highlights the evolution of the pharmaceutical landscape across multiple therapeutic frontiers. In metabolic disease, next-generation therapies are advancing oral delivery, novel hormonal mechanisms and broader applications across comorbid conditions. With obesity drug sales projected to reach USD 150 billion by 2035, companies will need to demonstrate real-world effectiveness, address payer considerations and differentiate through safety, convenience and clinical value.

Rare disease development is also expanding beyond oncology into neurological, psychiatric and hematologic conditions. Success in these ultra-small populations requires early patient identification, targeted engagement and an evidence-driven approach, while navigating increasingly complex regulatory pathways in the United States and Europe. Precision oncology and immunology are advancing in tandem, with innovations such as protein degraders, oral immunology agents, and next-generation targeted therapies enhancing specificity and improving patient access.

The report highlights the increasing importance of delivery innovation, including extended-release formulations and oral alternatives to injectable drugs, which improve adherence and real-world outcomes. Meanwhile, Mainland China is emerging as both a critical commercial market and a source of global innovation, with domestic developers advancing competitive therapies that are shaping global strategies in oncology, metabolic disease and immunology.

Access the Drugs to Watch 2026 report from Clarivate, here.

For more Drugs to Watch updates and analyses throughout the year, visit Drugs to Watch and follow Clarivate for Life Sciences & Healthcare on LinkedIn and X. Join the conversation, using #DrugstoWatch.

To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, visit here.

Methodology

The Drugs to Watch 2026 report identifies therapies expected to achieve blockbuster status within five years or significantly transform treatment paradigms, with blockbusters defined as reaching USD 1 billion in annual sales. Over 160 Clarivate analysts reviewed hundreds of drugs across hundreds of diseases and markets using ten integrated, AI-enhanced datasets covering the full R&D and commercialization lifecycle. Each therapy was evaluated in its clinical and commercial context, considering approval or launch timing, trial results, regulatory status, market dynamics and competitive landscape.

Candidates included therapies in phase two or three development, preregistration, registration or early 2026 launch. Forecast sales, clinical trends and expert judgment were combined to identify the eleven Drugs to Watch for 2026. Therapies were then grouped into thematic categories including, metabolic innovation, women’s health, rare and chronic disease, and protein degraders. Drug snapshots draw from Clarivate landscape and forecast reports, Cortellis sales and clinical data, expert interviews, peer-reviewed publications and regional analyses, including Mainland China.

Data sources and contributors

Clarivate’s analysis relies on integrated datasets and tools trusted by global life sciences customers. Key sources include Cortellis Competitive Intelligence, Epidemiology Intelligence, BioWorld, Cortellis Regulatory Intelligence, Cortellis Clinical Trials Intelligence, Cortellis Deals Intelligence and DRG Market Assessment, which includes Disease Landscape and Forecast, Access and Reimbursement, and China In-Depth. Combined with expert analyst insight, these resources provide a comprehensive, transparent foundation for identifying the therapies most likely to transform patient care and shape the global pharmaceutical market in 2026.

About Clarivate
Clarivate is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare.  For more information, please visit clarivate.com.

Media Contact:
Catherine Daniel
Director, External Communications, Life Sciences & Healthcare
newsroom@clarivate.com

MILAN, Jan. 6, 2026 /PRNewswire/ — As the 2026 season approaches, professional cycling enters a new phase of global collaboration. Elitewheels, together with its sister brand evolve, continues its partnership with UCI ProTeam Solution Tech – NIPPO – Rali, aiming to push performance, innovation, and international recognition to the next level.

A Stronger Second Year, Bigger Ambitions

After a successful debut season in 2025, Elitewheels renews its support for the team as it targets a potential Grand Tour future. Alongside Elitewheels‘ wheel sponsorship, evolve joins with its flagship CIMA performance road frameset, co-branded with its Panama distributor Rali.

The 2025 season proved the partnership’s competitive value. Racing on Elitewheels‘ Drive, Drive Helix SS and Velo TT wheelsets, the team delivered podiums, stage wins, and GC victories at events including the Tour of Slovenia and Tour of Hainan, while also making strong appearances at WorldTour races such as Strade Bianche, Milano–Sanremo, UAE Tour and Copenhagen Sprint.

“Our first year with Elitewheels exceeded expectations,” said Team Manager Serge. “The wheels delivered confidence everywhere, from crosswinds to full-gas sprints.” Seven-time champion sprinter Dušan Rajović echoed this sentiment, praising both stiffness and speed.

Precision Equipment for 2026

In 2026,Team Solution Tech – NIPPO – Rali will race on three Elitewheels flagship models:

Drive II: an all-round race wheel refined through CFD and Silverstone wind tunnel testing, saving ~5 watts compared to its predecessor.

Drive Helix CS: a premium all-rounder with helical airflow design, offering exceptional crosswind stability and precise stiffness.

Drive TT: a dedicated time-trial wheelset validated at Silverstone, optimized for sustained high-speed efficiency.

This equipment selection reflects Elitewheels‘ commitment to engineering refinement under real race pressure.

Alongside the ProTeam, the partnership also extends to Toscana Factory Devo Team, the official development squad of Solution Tech – NIPPO – Rali. The Devo Team will compete on Elitewheels Drive series and Rali–evolve co-branded CIMA framesets, ensuring young riders progress on the same high-performance equipment philosophy as the ProTeam.

Learn more: www.elite-wheels.com

evolve Steps Forward with CIMA

evolve brings its high-performance CIMA frameset to the partnership for 2026. Built with TORAY T1100, T800, and M40 carbon, the unpainted M-size frame weighs just 650g, balancing ultra-lightweight construction with race-level stiffness. Wind tunnel testing at Silverstone showed that the CIMA combined with KREUZA aerodynamic accessories saves 4.1 watts on average, translating to nearly 48 seconds over 40 km at 300W.

Founded by industry veterans and former UCI pro rider, evolve applies a rider-first philosophy focused on real-world performance. The CIMA has quickly earned recognition from both professionals and enthusiasts, establishing evolve as a serious contender in the global road market.

Learn more: www.evolvebicycles.com

Looking Ahead

More than a sponsorship, this partnership is a technology-driven collaboration. Engineers, riders, and mechanics work closely to refine aerodynamics, stiffness, and efficiency throughout the season.

Together, they represent a clear message: global cycling performance is evolving, and China’s engineering presence is now firmly part of the sport’s top tier.

LAS VEGAS, Jan. 6, 2026 /PRNewswire/ — Huion is excited to announce its presence at CES 2026 in Las Vegas, featuring the Kamvas Gen 3 series of pen displays and two new products.

This world-famous exhibition will take place over three days, from January 6 to January 9. If you’re interested in attending and want to get hands-on experience with Huion’s drawing displays, be sure to visit us at booth #21444.

Get to Know the Kamvas Gen 3 Family

Over the past year, Huion has focused on evolving the Kamvas lineup into its third generation. This series of Kamvas displays features Huion’s cutting-edge PenTech 4.0 technology, nano-etched Canvas Glass, multiple color modes, and high color accuracy, all aimed at delivering a comprehensive professional experience for illustrators, designers, and independent studios. The exclusive features and technologies of the Gen 3 lineup have been validated and have received widespread acclaim within the creative community.

Currently, the Gen 3 family includes the Kamvas Pro 19 and Kamvas Pro 27, both released in early 2024, as well as the Kamvas 13 (Gen 3), Kamvas 16 (Gen 3), and the recently launched Kamvas Pro 24 (Gen 3) and Kamvas Pro 27 (144Hz).

The Pro editions support finger touch for intuitive use, making them convenient for professional artists. In contrast, the standard editions, such as the Kamvas 13 (Gen 3) and Kamvas 16 (Gen 3), are designed for intermediate artists, art students, and small business owners, offering an affordable price without compromising performance.

New Products Leak

Get a sneak peek at Huion’s upcoming products! Huion will release two new items in the coming months: a 22-inch Gen 3 drawing display and a 12-inch 2K Android tablet. The pen display is expected to be an affordable alternative for desktop artists, while the tablet will feature PenTech 4.0 and AG+AF glass, providing an authentic pen-on-paper experience and sharp visuals even on a mobile device. These products are worth the wait!

Huion will showcase all of these devices at CES 2026. Visit our booth to try out the tablets! For more details about the display, follow our Instagram account @huiontablet or visit Huion’s official website at huion.com.

About Huion

Huion is an industry-leading innovator and manufacturer of cost-effective, high-quality pen tablets, pen displays, and standalone tablets designed for digital artists and designers worldwide.